EUVIMEDEUVIMED entdecken
Open Access

Preliminary Data From a Geriatrician‐Led Program for Orthopedic Co‐Managed Hip Fracture Patients Using Zoledronic Acid

Karen Chahal iD, Jessica Nguyen, Diviya Rajesh, Trevor McBroom, Katiri T Wagner, Michael McTague, Lewis Lipsitz, Edward Kenneth Rodriguez, John Wixted, Sarah D Berry

Journal of the American Geriatrics Society · 2025

DOI: 10.1111/jgs.70060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Geriatrics Society, 2025. Verfasst von Karen Chahal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Department of Medicine, Division of Gerontology & Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Zoledronic Acid, Hip Fractures, Bone Density Conservation Agents, Osteoporosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, All of Us Research Program NIH (US) MSTAR, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hip fractures are increasing as the U.S. population ages and result in significant morbidity, mortality, and cost. Despite guidelines recommending osteoporosis treatment after hip fracture, few patients receive treatment. To address this unmet need, our large, tertiary care, academic hospital initiated an inpatient osteoporosis treatment program with Zoledronic Acid (ZA) led by a single geriatrician co‐managing patients with hip fracture admitted to the orthopedic trauma service. This study describes the program's implementation and preliminary data.

Methods

A prospective cohort of older adults (>/= 65 years) with surgically repaired hip fractures at a single academic center were included from September 12th, 2022, through May 17th, 2024. The ZA program was initiated by geriatrics in collaboration with other specialties, including nursing and pharmacy. Co‐managed hip fracture patients were screened for ZA. Eligibility criteria included creatinine clearance >/= 35 mL/min and Vitamin D level >/= 20 ng/mL. The RE‐AIM framework was utilized to evaluate the program's implementation: Reach (number of patients admitted, screened and eligible), effectiveness (eligible patients who received ZA, reasons for ineligibility), adoption (time spent) and implementation (program cost).

Results

During a twenty‐month period, 232 hip fracture patients with a mean age of 83.8 years were admitted to co‐managed care, of which 74% were female. 148 patients were screened for ZA; 67 (45.3%) were eligible, and 58 (39.2%) received ZA prior to hospital discharge. The most common reasons for ineligibility were low vitamin D (32.1%), inadequate kidney function (21%) and previous or current osteoporosis treatment in the outpatient setting (29.6%). No adverse reactions or delays in discharge were noted among treated patients. On average, 30 min were spent on screening and treatment.

Conclusion

A co‐managed inpatient ZA program led by a single geriatrician appears to be a feasible strategy to treat osteoporosis among hospitalized patients with hip fracture.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zoledronic AcidHip FracturesBone Density Conservation AgentsOsteoporosisGeriatriciansHumansFemaleAgedMaleProspective StudiesAged, 80 and over

Stichwörter der Autor:innen

co‐managed carehip fractureinpatientosteoporosiszoledronic acid

Substanzen

Zoledronic AcidBone Density Conservation Agents

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Department of Medicine, Division of Gerontology & Harvard Medical School, Boston, Massachusetts, USA.
  • University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Harvard Combined Orthopedic Residency Program Harvard Medical School, Boston, Massachusetts, USA.
  • Beth Israel Deaconess Medical Center, Department of Orthopedic Surgery, Division of Orthopedic Trauma & Harvard Medical School, Boston, Massachusetts, USA.
  • Hinda and Arthur Marcus Institute for Aging Research and Department of Medicine, Hebrew SeniorLife, Boston, Massachusetts, USA.

ORCID-Profile: Karen Chahal

Förderung

  • NIA NIH HHS
  • All of Us Research Program NIH (US) MSTAR
  • National Institute on Aging
  • All of Us Research Program

Zitieren

APA

Chahal, K., Nguyen, J., Rajesh, D., McBroom, T., T Wagner, K., McTague, M., Lipsitz, L., Rodriguez, E. K., Wixted, J., & Berry, S. D. (2025). Preliminary Data From a Geriatrician‐Led Program for Orthopedic Co‐Managed Hip Fracture Patients Using Zoledronic Acid. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.70060

Vancouver

Chahal K, Nguyen J, Rajesh D, McBroom T, T Wagner K, McTague M, et al. Preliminary Data From a Geriatrician‐Led Program for Orthopedic Co‐Managed Hip Fracture Patients Using Zoledronic Acid. Journal of the American Geriatrics Society. 2025. doi:10.1111/jgs.70060

BibTeX
@article{Chahal2025,
  author = {Chahal, Karen and Nguyen, Jessica and Rajesh, Diviya and McBroom, Trevor and T Wagner, Katiri and McTague, Michael and Lipsitz, Lewis and Rodriguez, Edward Kenneth and Wixted, John and Berry, Sarah D},
  title = {Preliminary Data From a Geriatrician‐Led Program for Orthopedic Co‐Managed Hip Fracture Patients Using Zoledronic Acid},
  journal = {Journal of the American Geriatrics Society},
  year = {2025},
  doi = {10.1111/jgs.70060}
}
Kostenlos starten →